Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis

Main Article Content

L Stein-Gold
B Elewski
Z Draelos
T Lin


Halobetasol, Tazarotene, Psoriasis


Abstract not available.


1. Nestle FO, et al. N Engl J Med. 2009;361(5):496‑509.
2. Hotard RS, et al. J Am Acad Dermatol. 2000;42(4):620‑623.
3. Gottlieb AB, et al. Int J Womens Dermatol. 2019;5(3):141‑150.
4. Stein Gold L, et al. J Am Acad Dermatol. 2018;79(2):287‑293.
5. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855‑861.

Most read articles by the same author(s)

1 2 > >>